Basic Sinequan Information

• INN (International Nonproprietary Name): Doxepin.
• Brand Names Available In Canada (English): Not specified.
• ATC Code: N06AA12.
• Forms & Dosages: Capsules 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; oral solution 10 mg/mL in some markets; Silenor tablets 3 mg and 6 mg for insomnia.
• Manufacturers In Canada (English): Not specified.
• Registration Status In Canada (English): Registered as prescription only (Rx); generic approval is prevalent.
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Highlights (Canadian & International 2022–2025)

Patients ask whether doxepin still has a place given newer antidepressants and sleep aids.

Recent literature from 2022–2025 has refined doxepin’s niche as a tricyclic antidepressant with strong antihistaminic and anticholinergic effects.

Systematic reviews continue to show that tricyclic antidepressants are effective for major depressive disorder but are less commonly used first line than SSRIs because of tolerability differences.

Low‑dose doxepin preparations, specifically Silenor 3–6 mg, retain evidence for chronic insomnia management.

Canadian pharmacoepidemiology shows declining TCA prescribing in urban primary care, with continued use in rural and geriatric practice for neuropathic pain, insomnia and refractory depression.

Sinequan capsules (10–100 mg) were discontinued in the USA, while generics from manufacturers such as Mylan and Teva remain available globally and support Canada’s generic supply chain.

Patient‑centred studies highlight the importance of shared decision‑making, clear consent about anticholinergic burden, and monitoring for suicidality in younger adults.

Clinical Effectiveness In Canada (Health Canada & Formularies)

Patients often want to know whether doxepin is an accepted choice on provincial drug plans.

Health Canada classifies doxepin as prescription only, and product authorisations list specific Drug Identification Numbers (DINs) for brands and generics.

Clinical effectiveness in Canadian practice conforms with international guidance: doxepin is effective at conventional TCA doses for depression and anxiety, while Silenor 3–6 mg is indicated for insomnia.

Provincial formularies differ; some list generic doxepin under limited benefits or exceptional access for second‑line depression and neuropathic pain.

Pharmacists in national chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu commonly dispense generics, and coverage often requires special authorisation.

Generics supplied by manufacturers like Mylan and Teva continue to support availability in Canada despite the US Sinequan discontinuation.

When prescribing off‑formulary, clinicians should document the clinical rationale and monitor older adults for anticholinergic harms.

• Health Canada Approval Status: Prescription only; generic approval is prevalent.
• DIN Search Recommendation: Check the Health Canada Drug Product Database for specific DINs before dispensing.
• Provincial Formulary Check: Verify Ontario Drug Benefit, BC PharmaCare and RAMQ listings and special authorisation rules.

Indications & Expanded Uses (Approved Vs Off‑Label In Canada)

People want clarity: when is doxepin approved, and when is it used off‑label?

• Approved: Depression and anxiety where TCAs are indicated, and insomnia for Silenor 3–6 mg tablets.
• Off‑Label: Neuropathic pain, chronic urticaria refractory to antihistamines, and low‑dose insomnia when benzodiazepines are unsuitable.

Clinicians should check Health Canada monographs and the DIN label for indication specifics before prescribing.

For patients under 12, doxepin is not recommended; for adolescents aged 12 and over the lowest effective dose should be used with psychiatry input when needed.

In Indigenous and remote communities, safety and access constraints often push clinicians to choose non‑sedating or locally manageable options.

Composition & Brand Landscape (Active Ingredients, Brands, DINs)

Patients frequently mix up brand names and strengths; verification at the pharmacy prevents dosing errors.

The active ingredient across all products is doxepin hydrochloride in various formulations.

Known brand names in international markets include Sinequan (capsules 10–100 mg), Silenor (tablets 3–6 mg for insomnia), Quitaxon and Doquel.

Mylan and Teva are major generic suppliers of doxepin capsules worldwide.

Pharmacists should confirm strength and formulation at pickup to avoid confusion between antidepressant doses and low‑dose insomnia tablets.

Contraindications & Special Precautions (Canadian Context)

Safety questions are common, especially for older adults and patients with multiple medicines.

• Absolute Contraindications: Known hypersensitivity to doxepin or other TCAs.
• Absolute Contraindications: Narrow‑angle glaucoma.
• Absolute Contraindications: Urinary retention.
• Absolute Contraindications: MAOI use within the past 14 days.

• Relative Contraindications: Elderly patients due to higher risk of confusion, sedation and falls.
• Relative Contraindications: Severe hepatic or renal impairment; dose reduction advised.
• Relative Contraindications: History of suicidality; monitor closely.
• Relative Contraindications: Cardiac conduction disorders or arrhythmias; baseline ECG recommended for risk patients.
• Relative Contraindications: Severe prostatic hypertrophy and pregnancy or lactation — use only if clearly needed.

In Canadian practice, prescribers should weigh anticholinergic burden against polypharmacy common in older adults and consider Beers Criteria guidance.

For remote or Indigenous communities where ECG access may be limited, extra caution is warranted before initiating higher doses.

Dosage Guidelines (Standard Canadian Schedules & Adjustments)

Common patient concerns include starting dose, titration speed, and what to do if they miss a dose.

For depression and anxiety, a typical adult starting dose is around 75 mg per day, given in divided doses or at bedtime, with a usual range of 75–150 mg per day and a maximum up to 300 mg per day.

For insomnia, Silenor is dosed at 3–6 mg at bedtime.

Children under 12 are not recommended to use doxepin; adolescents 12 and older should use the lowest effective dose with specialist input when necessary.

Elderly patients should start low, for example 25–50 mg per day, then titrate slowly while watching for anticholinergic effects.

• Start low.
• Assess after 1–2 weeks.
• Increase slowly every 1–2 weeks if needed.
• Monitor for side effects and obtain ECG when higher doses or cardiac risk are present.

Pharmacists should advise patients on missed‑dose handling: take as soon as remembered unless it is near the next scheduled dose, and do not double doses.

When stopping doxepin, recommend gradual withdrawal to reduce the risk of discontinuation symptoms.

Interactions Overview (Food, Alcohol, Drugs)

Patients often ask which drugs or OTCs to avoid while taking doxepin.

Pharmacists should check provincial prescription records and ask about seasonal OTC cold medicines that may add anticholinergic burden.

Rural patients who self‑medicate can be at higher interaction risk; encourage consults at community pharmacies such as Shoppers Drug Mart or Rexall.

Cultural Perceptions & Patient Habits (Canada‑Focused)

What do Canadian patients actually say about doxepin?

Online forums and provincial mental health groups report mixed experiences: many appreciate the sedating benefit for sleep, while others worry about dry mouth, cognitive slowing and weight gain.

Seniors especially express concern about anticholinergic effects and fall risk.

Urban patients often have faster access to psychiatry or collaborative care teams, whereas clinicians serving rural and Indigenous communities may avoid higher doses due to limited specialist and ECG access.

Cost and formulary coverage matter to Canadians because of the public health system and out‑of‑pocket sensitivities.

• Expected Onset: Antidepressant effects may take 1–3 weeks; insomnia benefit at low dose can be observed sooner.
• Common Side Effects: Drowsiness, dry mouth, constipation, blurred vision.
• Monitoring Signs: New heart palpitations, excessive daytime somnolence, or worsening mood require prompt review.
• When To Seek Urgent Care: Severe chest pain, fainting, seizures, or suicidal thoughts.

Availability & Pricing Patterns (Pharmacies, Online, Cross‑Border)

Many patients ask whether Sinequan or doxepin is easy to get and what it costs.

Although Sinequan was discontinued in the USA, generics from Mylan and Teva remain the primary supply for Canadian pharmacies.

Major chains such as Shoppers Drug Mart, Rexall, London Drugs and Jean Coutu typically stock generic doxepin; Silenor may be obtained via specialty distributors.

Provincial formularies influence coverage and cost, with some plans requiring special authorisation for Silenor or for higher doses.

Cross‑border importing is legally restricted and can risk customs seizure; historically branded US prices were lower, but the generic market has narrowed price differences.

In our online pharmacy, sinequan is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Rural pharmacies may occasionally face stock outages, so prescribers are advised to include equivalent DINs for substitution where possible.

Patients on public plans should confirm ODB, PharmaCare or RAMQ rules and potential co‑pays with their pharmacist before filling prescriptions.

Comparable Medicines & Prescribing Preferences (Alternatives In Canada)

Patients and prescribers often wonder what the practical alternatives are.

Alternatives include other TCAs such as amitriptyline, nortriptyline and imipramine, and first‑line SSRIs such as sertraline or fluoxetine which are preferred for tolerability.

For insomnia, low‑dose doxepin (Silenor) is an alternative to non‑benzodiazepine hypnotics or melatonin in certain patients.

• Pros Of Doxepin: Efficacy for depression and targeted low‑dose insomnia benefit.
• Cons Of Doxepin: Anticholinergic burden, sedation, and cardiac interaction concerns.
• Pros Of SSRIs: Better tolerability and fewer anticholinergic effects.
• Cons Of SSRIs: Different side‑effect profile, including sexual dysfunction for some patients.

For neuropathic pain many provincial formularies prefer gabapentinoids or SNRIs such as duloxetine as initial options, reserving TCAs for patients who fail first‑line therapies.

FAQ — Common Canadian Patient Questions & Answers

• Q: Is doxepin covered by my provincial plan?

  A: Coverage varies; check your provincial formulary (ODB, BC PharmaCare, RAMQ) and provide the DIN to your pharmacist; special authorisation may be required.

• Q: Can I drink alcohol while taking doxepin?

  A: Avoid or minimise alcohol because it increases sedation and fall risk.

• Q: Will doxepin make me sleepy in the day?

  A: At antidepressant doses daytime sleepiness is common; low‑dose Silenor targets bedtime sleep with less daytime sedation when used at 3–6 mg.

• Q: What if I miss a dose?

  A: Take it as soon as you remember unless it is near the next dose; do not double up doses.

• Q: How long before it works?

  A: Antidepressant benefit often appears over 1–3 weeks; insomnia improvement with low dose may be seen sooner.

For coverage checks, ask your pharmacist for the DIN from the prescriber and request a formulary lookup at your local Shoppers Drug Mart, Rexall or Jean Coutu store.

Guidelines For Proper Use (Pharmacist & Provincial Tips)

Pharmacists want a concise checklist to support safe dispensing and monitoring.

• Verify indication and DIN before dispensing.
• Review the patient’s full medication list for MAOIs, QT‑prolonging drugs, and anticholinergics.
• Recommend a baseline ECG for patients with cardiac risk or when higher doses are planned.
• Counsel on anticholinergic side effects and advise orthostatic precautions.
• Advise a slow taper on discontinuation to prevent withdrawal symptoms.

Provincial tips include documenting clinical rationale for off‑formulary requests and using formularies to select cost‑effective DINs.

For rural or remote patients arrange local monitoring through telehealth ECG referrals and pharmacist follow‑ups, and provide bilingual counselling where required.

• Monitoring Schedule: Week 1 check for tolerability, Month 1 review response, then quarterly assessments for ongoing therapy.
• Red Flags: New arrhythmia symptoms, severe sedation, or suicidal ideation require urgent clinical review.

Storage: Keep at room temperature (15–30°C) in original packaging to maintain stability.

Delivery Across Canada (English)